Rankings · updated 2026-08-24
Brand-name GLP-1s online: the FDA-approved routes
Last verified 2026-08-24 · methodology · conflict-of-interest disclosure · dataset: open JSON
Two manufacturer-direct programs anchor the brand-name self-pay market on file: LillyDirect (Zepbound vials, from $299/mo recorded) and NovoCare (Wegovy, $349/mo verified, dose-tiered with conditions) — FDA-approved products, trial evidence that belongs to the exact product you receive, at two to four times compounded prices. Figures are manufacturer-published tiers verified on the live pages 2026-08-25, with offer conditions and expirations stored on each row (Zepbound card terms through 2026-12-31; Wegovy 4 mg pill promo boundary 2026-08-31). Last verified 2026-08-24.
| Provider | Medication | From / mo (recorded) | Status | Source · checked |
|---|---|---|---|---|
| Ro | tirzepatide | $299 | Reported | ro.co · 2026-08-25 |
| LillyDirect | tirzepatide | $299 | Verified | zepbound.lilly.com · 2026-08-25 |
| NovoCare | semaglutide | $349 | Verified | novocare.com · 2026-08-25 |
| Calibrate | semaglutide | — | Reported | joincalibrate.com · 2026-08-25 |
What brand buys, plainly
FDA review of the finished product, the device (or manufacturer vial program), and trial evidence that transfers because it was generated on the thing in your hand. What it costs: the gap versus compounded runs $180–$360/month at current recorded list prices. Insurance can invert this entirely — covered brand beats cash compounded — which is what the coverage hub is for.
Best for
- Anyone with coverage, a savings-card path, or a hard requirement for FDA-approved product
Not best for
- Pure cash-price shoppers — the compounded list starts ~70% lower
Unverified — listed, not ranked
Both rows are recorded manufacturer list prices, not first-party verifications — they sit in the queue like everyone else.
Update log
- 2026-08-24 — Page created from the live dataset per the Pass-12 audit; sortable columns added.